GoAI
Get started
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc.

ELDN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.45

−$0.07 · -1.99%

Aug 21, 4:00 PM ET

ELDN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

32

Expensive

Momentum

62

Gaining

Sentiment

45

Mixed

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David-Alexandre C. Gros
Listed since
Sep 17, 2014
Employees
33

Market position

Day range

Current $3.45

52-week range

Current $3.45

Open
$3.56
Previous close
$3.52
Volume
743.92K
0.55× average
Average volume
1.36M
Average daily volume
Market cap
266.3M USD
Beta
0.96
Market reference 1
50-day average
$3.7202
-7.26% below average
200-day average
$2.8977
+19.06% above average

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-24.39%
11 comparable reports
Latest EPS result
-0.27
Estimate -0.16 · Miss by 70.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.27-0.48-0.68Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.64, estimate -0.32, surprise -100.00%, Miss. Q2 2025, reported May 14, 2025: actual -0.08, estimate -0.28, surprise +71.43%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.13, estimate -0.23, surprise +43.48%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.21, estimate -0.22, surprise +4.55%, Beat. Q1 2026, reported Mar 19, 2026: actual -0.1, estimate -0.2, surprise +50.00%, Beat. Q2 2026, reported May 13, 2026: actual -0.33, estimate -0.22, surprise -50.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.27, estimate -0.158, surprise -70.89%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates589.44K447.36K305.28K163.2KQ1 '24Q1 '25
Q1 2024, reported Mar 28, 2024: actual 560K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 20, 2025: actual 192K USD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Oct 5, 2020

1:18

Stock split

Effective May 11, 2017

1:9

ELDN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ELDN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.39M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
7.06M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.89M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.55M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.46M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
939.31K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
693.08K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
324.39K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research ELDN

research.disclaimer